JP2025515706A5 - - Google Patents
Info
- Publication number
- JP2025515706A5 JP2025515706A5 JP2024566219A JP2024566219A JP2025515706A5 JP 2025515706 A5 JP2025515706 A5 JP 2025515706A5 JP 2024566219 A JP2024566219 A JP 2024566219A JP 2024566219 A JP2024566219 A JP 2024566219A JP 2025515706 A5 JP2025515706 A5 JP 2025515706A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- fluoro
- amount
- composition according
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025182180A JP2026021422A (ja) | 2022-05-11 | 2025-10-29 | Ｇｌｐ１医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263340591P | 2022-05-11 | 2022-05-11 | |
| US63/340,591 | 2022-05-11 | ||
| PCT/US2023/021637 WO2023220109A1 (en) | 2022-05-11 | 2023-05-10 | Glp1 pharmaceutical compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025182180A Division JP2026021422A (ja) | 2022-05-11 | 2025-10-29 | Ｇｌｐ１医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025515706A JP2025515706A (ja) | 2025-05-20 |
| JP2025515706A5 true JP2025515706A5 (cg-RX-API-DMAC7.html) | 2025-06-18 |
| JP7767651B2 JP7767651B2 (ja) | 2025-11-11 |
Family
ID=86732348
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024566219A Active JP7767651B2 (ja) | 2022-05-11 | 2023-05-10 | Ｇｌｐ１医薬組成物 |
| JP2025182180A Pending JP2026021422A (ja) | 2022-05-11 | 2025-10-29 | Ｇｌｐ１医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025182180A Pending JP2026021422A (ja) | 2022-05-11 | 2025-10-29 | Ｇｌｐ１医薬組成物 |
Country Status (17)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20250009A1 (es) * | 2022-05-11 | 2025-01-07 | Lilly Co Eli | Composiciones de comprimidos de glp1 |
| EP4777197A2 (en) | 2023-09-14 | 2026-07-22 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| KR20260118441A (ko) * | 2023-11-21 | 2026-07-30 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 헤테로시클릭 화합물, 이의 제조 방법 및 의약에서 이의 응용 |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| CA2434641A1 (en) * | 2001-01-18 | 2002-08-22 | Pharmacia And Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| AU2007293032A1 (en) * | 2006-09-08 | 2008-03-13 | Merck Sharp & Dohme Corp. | Liquid pharmaceutical formulations for oral administration of a CGRP antagonist |
| JOP20190060A1 (ar) * | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| JP7461104B2 (ja) * | 2017-11-29 | 2024-04-03 | 中外製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
| PL3984523T3 (pl) * | 2018-12-07 | 2026-02-02 | Neurocrine Biosciences, Inc. | Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy |
| US11884672B2 (en) * | 2019-05-14 | 2024-01-30 | Vertex Pharmaceuticals Incorporated | Modulators of alpha-1 antitrypsin |
| JP7796115B2 (ja) * | 2020-09-09 | 2026-01-08 | クリネティックス ファーマシューティカルズ，インク． | ソマトスタチン調節因子の製剤 |
| PE20250009A1 (es) * | 2022-05-11 | 2025-01-07 | Lilly Co Eli | Composiciones de comprimidos de glp1 |
-
2023
- 2023-05-10 EP EP23729579.5A patent/EP4522129A1/en active Pending
- 2023-05-10 JP JP2024566219A patent/JP7767651B2/ja active Active
- 2023-05-10 AU AU2023269995A patent/AU2023269995A1/en active Pending
- 2023-05-10 CA CA3253043A patent/CA3253043A1/en active Pending
- 2023-05-10 US US18/864,210 patent/US20250302809A1/en active Pending
- 2023-05-10 PE PE2025002371A patent/PE20260136A1/es unknown
- 2023-05-10 WO PCT/US2023/021637 patent/WO2023220109A1/en not_active Ceased
- 2023-05-10 KR KR1020247040462A patent/KR20250002778A/ko active Pending
- 2023-05-10 PE PE2024002463A patent/PE20251285A1/es unknown
- 2023-05-10 IL IL316629A patent/IL316629A/en unknown
- 2023-05-10 CN CN202380039380.7A patent/CN119173255A/zh active Pending
- 2023-05-11 TW TW113144409A patent/TW202508581A/zh unknown
- 2023-05-11 AR ARP230101165A patent/AR129296A1/es unknown
- 2023-05-11 TW TW112117510A patent/TWI867526B/zh active
-
2024
- 2024-11-05 JO JOJO/P/2024/0245A patent/JOP20240245A1/ar unknown
- 2024-11-06 CL CL2024003392A patent/CL2024003392A1/es unknown
- 2024-11-08 MX MX2024013839A patent/MX2024013839A/es unknown
- 2024-11-08 CO CONC2024/0015285A patent/CO2024015285A2/es unknown
- 2024-11-11 DO DO2024000232A patent/DOP2024000232A/es unknown
-
2025
- 2025-10-29 JP JP2025182180A patent/JP2026021422A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026021422A5 (cg-RX-API-DMAC7.html) | ||
| IL316629A (en) | GLP1 drug compounds | |
| RU2574018C2 (ru) | Легко дозируемый твердый препарат | |
| JPH0399016A (ja) | 二重被覆顆粒 | |
| CN107049979B (zh) | 易服用性固体制剂 | |
| JP5160423B2 (ja) | 水易溶性薬物含有球状素顆粒の製造方法 | |
| IL316478A (en) | GLP1 tablet preparations | |
| CA2905011A1 (en) | Extended-release topiramate capsules | |
| CN102091051A (zh) | 一种别嘌醇双释放制剂及其制备方法 | |
| US20180015080A1 (en) | Compositions and methods for treatment in parkinson's disease patients | |
| KR20230057388A (ko) | Sglt-2 억제제와 안지오텐신 수용체 길항제의 조성물 및 이의 용도 | |
| TW201414508A (zh) | 含５－氯－ｎ－（｛（５ｓ）－２－側氧－３－［４－（３－側氧－４－嗎啉基）苯基］－１，３－□唑啶－５－基｝甲基）－２－噻吩甲醯胺之醫藥投遞型式 | |
| JP2018118966A (ja) | ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。 | |
| JP2018118966A5 (cg-RX-API-DMAC7.html) | ||
| CN108201529B (zh) | 一种含有尿酸转运蛋白抑制剂的药物组合物及其制备方法 | |
| JPH0692849A (ja) | フラン誘導体を含有する医薬組成物 | |
| TW201402156A (zh) | 膠囊劑 | |
| WO2015008825A1 (ja) | 口腔内崩壊錠 | |
| JP4902928B2 (ja) | 製剤の安定化方法 | |
| EP3973030A1 (en) | Compositions and methods for the treatment and mitigation of alcohol-induced skin flushing | |
| JP2017119714A (ja) | メドキソミル基を有するプロドラッグを含有するフィルムコーティング製剤 | |
| JP2023083990A (ja) | シタグリプチンリン酸塩無水物経口製剤の安定化方法および用途 | |
| JP2024503689A5 (cg-RX-API-DMAC7.html) | ||
| WO2017056104A1 (en) | Stable pharmaceutical compositions of teriflunomide | |
| KR102330953B1 (ko) | 소듐-1-[6-(모르폴린-4-일)피리미딘-4-일]-4-(1h-1,2,3-트리아졸-1-일)-1h-피라졸-5-올레이트를 함유하는 제약 투여 형태 |